BOSTON, June 4, 2013 (GLOBE NEWSWIRE) -- The American Cancer Society estimates that every 7 minutes someone is diagnosed with melanoma.
Tauriga Sciences, Inc. (OTCQB:TAUG) ("Tauriga"), a diversified life sciences company building a valuable portfolio of medical technologies, today announced the public launch of Cambridge, Massachusetts-based Constellation Diagnostics Inc. ("Constellation"), developer of a camera-based technology with the goal of preventing skin cancer through early detection.
Tauriga's COO Dr. Stella Sung commented, "Constellation's novel imaging system has relevance to millions of people worldwide who are at risk for skin cancer. Skin cancer is the most common of all cancers and represents nearly half of all cancers in the United States. We are excited about the potential of this dermatologist-endorsed product to save many lives through comprehensive and early tracking and detection."
Constellation Diagnostics' CEO Christian Bailey stated, "Computer Vision has already revolutionized other industries. The vision systems that Constellation builds on are much like the ones that proved effective in sending a driverless car coast-to-coast, which we expect will allow us to demonstrate a product within one year."
Tauriga announced a Memorandum of Understanding ("MOU") with Constellation on May 02, 2013 and can earn an equity stake in Constellation of up to a 35%; as previously disclosed, the Company has made an initial investment. The public launch and Constellation's website includes an overview of the technology platform, information on potential overall market size, and team biographies: www.constellationcare.com.
About Tauriga Sciences, Inc.:
Tauriga Sciences, Inc. is a life sciences company that focuses on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare. The mission of the Company is to acquire and build a diversified portfolio of medical technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at www.taurigasciences.com.
About Constellation Diagnostics, Inc.
Constellation Diagnostics Inc. is developing a novel, imaging-based diagnostic technology for use in predictive and preventative oncology. Constellation empowers patients to conduct quick, cost-effective, full body scans every month in the privacy of their homes, or in health clubs, doctors' offices and other commercial settings. Signs of skin cancer are detected as early as possible, dramatically increasing patient survival rates. Unlike applications currently on the market, Constellation is the only solution that detects changes in moles over time - which is critical to early detection. The Constellation team is collaborating with researchers at Massachusetts Institute of Technology ("MIT") and Harvard University ("Harvard"). For more information, please see www.constellationcare.com.
About Curated Innovation
Curated Innovation is a Cambridge-based nonprofit innovation lab which brings together leading university scientists, donors, and investors to create technology that will make an impact on a health issue they care about. Curated Innovation already has projects underway in the fields of breast cancer, skin cancer, and Parkinson's disease. For more information, please see www.curatedinnovation.org.
DISCLAIMER:
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission.
This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.